Allchem Lifescience Ltd. IPO Details
Allchem Lifescience Ltd. was incorporated on January 12, 2017. The company manufactures active pharmaceutical ingredient (API) intermediates and specialty chemicals, specializing in key starting materials (KSMs) and generic API intermediates
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 7.2 M | - | - | ₹1,900.0 M | DRHP DOC |
Allchem Lifescience issue details
Allchem Lifescience has 7.2 M shares on offer
Allchem Lifescience IPO issue size is ₹ 1,900.0 M
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
Allchem Lifescience IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE and BSE |
Allchem Lifescience NUMBER OF SHARES ON OFFER
Allchem Lifescience FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from Operations (Rs in millions) | Cash Flow from Operations (Rs in millions) | Free Cash Flow (Rs in millions) | Margins |
| H1FY25 | 108.9 | 784.5 | 131.7 | 28.8 | 41.0% |
| FY24 | 234.1 | 1,374.2 | 407.2 | -14.7 | 38.1% |
| FY23 | 179.9 | 1,057.2 | 283.9 | -456.1 | 28.8% |
| FY22 | 141.4 | 1,081.0 | 108.1 | -259.2 | 23.1% |
Allchem Lifescience INFORMATION ON IPO ISSUE
About Allchem Lifescience
Allchem Lifescience Ltd. was incorporated on January 12, 2017. The company manufactures active pharmaceutical ingredient (API) intermediates and specialty chemicals, specializing in key starting materials (KSMs) and generic API intermediates
Object of the Issue
- Repayment and/ or pre-payment, in full or part, of certain borrowings availed by the company
- General corporate purposes
Allchem Lifescience - PROMOTERS
| Name |
|---|
| Bipin Patel |
| Kantilal Ramanlal Patel |
| Manisha Bipin Patel |
| Aditi Patel |
Allchem Lifescience Book Running Lead Manager
Emkay Global Financial Services Limited
allchem.ipo@emkayglobal.com
Allchem Lifescience Registrar to the Offer
MUFG Intime India Private Limited
allchemlifescience.ipo@in.mpms.mufg.com
Allchem Lifescience Strengths
Diversified customer base
A key competitive strength is the company’s diversified customer base. As of December 31, 2024, it serves customers across 13 Indian states and 22 countries worldwide
Focus on developing new products
The company prioritizes developing new organic chemical compounds and innovative products. As of December 31, 2024, its product development team consists of 8 skilled employees, including experienced professionals with advanced degrees in science and engineering
Supply chain management
Due to the critical applications of its products, the company adheres to strict quality standards and compliance requirements, including Drug Master File (DMF) filings. It undergoes rigorous audits by customers and regulatory agencies like USFDA to qualify as an approved supplier
Allchem Lifescience Risks
Geographically concentrated
The company's revenue is concentrated in specific geographical regions in India. Any inability to sustain or expand operations in these areas may adversely impact its business, financial condition, cash flow, and growth prospects
Dependent on few suppliers
The company relies heavily on a few vendors without long-term contracts. Losing key vendors or facing challenges in procuring quality raw materials at competitive prices could negatively impact its business, revenue, and financial condition
Quality standards
Failure to meet customer quality standards could result in order cancellations, warranty claims, and financial liabilities, impacting the company's reputation, business, and financial condition
IPO FAQs
The promoters of the company are Bipin Patel, Kantilal Ramanlal Patel, Manisha Bipin Patel and Aditi Patel.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.